AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17925486 — intervention group
Group type: EXPERIMENTAL
Intervention: sBAFF
Number of subjects: 52
Study 17925486 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-dsDNA antibody
Number of subjects: 52
Study 17925486 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-2Ralpha
Number of subjects: 52
Study 17925486 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD13
Number of subjects: 52
Study 17925486 — intervention group
Group type: COMPARATOR
Intervention: biomarkers
Number of subjects: 52
Study 16213933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel tonsillectomy (US)
Number of subjects: 122
Study 16213933 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy (BD)
Number of subjects: 122
Study 12834513 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/d or more)
Number of subjects: 671
Study 12834513 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (effective dose for at least 9 to 12 months)
Number of subjects: 671
Study 11763941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction toothbrush
Number of subjects: 200
Study 11763941 — intervention group
Group type: COMPARATOR
Intervention: Dr. Best InterDent toothbrush
Number of subjects: 200
Study 11763941 — intervention group
Group type: COMPARATOR
Intervention: Crest DeepSweep toothbrush
Number of subjects: 200
Study 8857384 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlet policies and practices that may reduce the likelihood of sales to youth
Number of subjects: 15
Study 8857384 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlet characteristics, policies and practices
Number of subjects: 15
Study 1644325 — intervention group
Group type: EXPERIMENTAL
Intervention: Predigested nitrogen source (medium chain peptides)
Number of subjects: 12
Study 1644325 — intervention group
Group type: COMPARATOR
Intervention: Whole protein nitrogen source
Number of subjects: 12
Study 1644325 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 12
Study 1644325 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup with small bowel disease
Number of subjects: 12
Study 6677083 — intervention group
Group type: EXPERIMENTAL
Intervention: Social consequences information (videotaped message)
Number of subjects: 54
Study 6677083 — intervention group
Group type: COMPARATOR
Intervention: Control information (videotaped message)
Number of subjects: 54
Study 31403816 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy for CSOs
Number of subjects: 100
Study 31403816 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study 30117129 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol 0.5 μg
Number of subjects: 24
Study 30117129 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol 0.75 μg
Number of subjects: 24
Study 30117129 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (both doses)
Number of subjects: 24
Study 30117129 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol
Number of subjects: 24
Study 26747682 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized, evidence-based smoking cessation intervention
Number of subjects: 15
Study 26747682 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 15
Study 24473248 — intervention group
Group type: EXPERIMENTAL
Intervention: VRT and tDCS
Number of subjects: 20
Study 24473248 — intervention group
Group type: COMPARATOR
Intervention: VRT and sham tDCS
Number of subjects: 20
Study 21120580 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (bevacizumab 5 mg/kg every 2 weeks, FOLFOX4 every 2 weeks)
Number of subjects: 84
Study 21120580 — intervention group
Group type: COMPARATOR
Intervention: FFG (bevacizumab 5 mg/kg every 2 weeks, FFG weekly for 6 weeks of an 8-week cycle)
Number of subjects: 84
Study 21120580 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 84
Study 21120580 — intervention group
Group type: COMPARATOR
Intervention: FFG
Number of subjects: 84
Study 21120580 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 and FFG
Number of subjects: 84
Study 19913311 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng 1 g
Number of subjects: 25
Study 19913311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hop extract 0.25 g, caramel color 0.05 g, and red ginseng flavor 0.03 g)
Number of subjects: 25
Study 16942792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal ultrasound
Number of subjects: 0
Study 16942792 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials and observational studies
Number of subjects: 0
Study 15788528 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity program
Number of subjects: 198
Study 15788528 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 11937315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubitecan 1.5 mg/m2 after overnight fasting
Number of subjects: 19
Study 11937315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubitecan 1.5 mg/m2 after a high calorie breakfast
Number of subjects: 19
Study 11937315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubitecan 1.5 mg/m2/day under fasting conditions for 5 consecutive days per week until disease progression
Number of subjects: 19
Study 10432133 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplementation (60 g of soy powder daily for 3 months)
Number of subjects: 104
Study 10432133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 7487440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 10
Study 7487440 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study 7487440 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 10
Study 7487440 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school
Number of subjects: 10
Study 7487440 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 10
Study 1835587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with buserelin (CAF regimen)
Number of subjects: 147
Study 1835587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with buserelin (CMF regimen)
Number of subjects: 147
Study 1835587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with buserelin
Number of subjects: 147
Study 1835587 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot buserelin
Number of subjects: 147
Study 1835587 — intervention group
Group type: COMPARATOR
Intervention: CMF alone
Number of subjects: 147
Study 6123719 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 16082
Study 6123719 — intervention group
Group type: COMPARATOR
Intervention: Control (Tetracycline ophthalmic ointment)
Number of subjects: 16082
Study 31389614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with adrenaline (5 μg.ml-1)
Number of subjects: 12
Study 31389614 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine without adrenaline
Number of subjects: 12
Study 31389614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 30570938 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI within two weeks after trauma
Number of subjects: 356
Study 30570938 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 356
Study 30570938 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CRP-test for acute cough
Number of subjects: 356
Study 27090108 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1000 mg/day)
Number of subjects: 15
Study 23461355 — intervention group
Group type: EXPERIMENTAL
Intervention: iCare Condition (ICC)
Number of subjects: 150
Study 23461355 — intervention group
Group type: COMPARATOR
Intervention: Education/Information‐Only Condition (EOC)
Number of subjects: 150
Study 21231862 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 5/30 mg oxycodone HCl/niacin tablets
Number of subjects: 405
Study 21231862 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 7.5/30 mg oxycodone HCl/niacin tablets
Number of subjects: 405
Study 21231862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 17522920 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused endoscopic parathyroidectomy (MIVAP technique) plus quick intraoperative parathormone assay (qPTHa)
Number of subjects: 40
Study 17522920 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic parathyroidectomy plus bilateral exploration
Number of subjects: 40
Study 16503695 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity group (MIG; n = 9)
Number of subjects: 29
Study 16503695 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity group (LIG; n = 12)
Number of subjects: 29
Study 16503695 — intervention group
Group type: COMPARATOR
Intervention: High-intensity group (HIG; n = 8)
Number of subjects: 29
Study 12948274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated Thai garlic extract tablet (1.12% allicin or 5.6 mg/tablet) once daily for 12 weeks
Number of subjects: 136
Study 12948274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 11006807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on learning (making a model of a volcano)
Number of subjects: 73
Study 11006807 — intervention group
Group type: COMPARATOR
Intervention: Demonstration teaching method (observing the making of a model of a volcano)
Number of subjects: 73
Study 9171769 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 100
Study 9171769 — intervention group
Group type: COMPARATOR
Intervention: Late presentation to the family doctor
Number of subjects: 100
Study 1543812 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole in the morning
Number of subjects: 6
Study 1543812 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole in the evening
Number of subjects: 6
Study 1543812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3457137 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy-Jet
Number of subjects: 21
Study 3457137 — intervention group
Group type: COMPARATOR
Intervention: Rubber cup and paste techniques
Number of subjects: 21
Study 30063589 — intervention group
Group type: COMPARATOR
Intervention: Immobilization protocol (postoperative forearm-based thumb-spica splint for 7 days, forearm-based thumb-spica cast for 5 weeks, custom forearm-based thermoplastic thumb-spica splint for 6 weeks)
Number of subjects: 223
Study 30063589 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization protocol (postoperative forearm-based thumb-spica splint for 7 days, forearm-based thermoplastic thumb-spica splint for 3 weeks, hand-based thumb-spica splint for 4 weeks)
Number of subjects: 223
Study 27780567 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental ONS (EONS, 20 g protein; 499 IU vitamin D3; 1.5 g CaHMB)
Number of subjects: 330
Study 27780567 — intervention group
Group type: COMPARATOR
Intervention: Control ONS (CONS, 14 g protein; 147 IU vitamin D3)
Number of subjects: 330
Study 24649963 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainees' self-assessments of their communication skills in religious/spiritual communication
Number of subjects: 541
Study 24649963 — intervention group
Group type: COMPARATOR
Intervention: Patients' reports of the occurrence of religious/spiritual communication
Number of subjects: 541
Study 20483060 — intervention group
Group type: EXPERIMENTAL
Intervention: MET + CBT
Number of subjects: 344
Study 20483060 — intervention group
Group type: EXPERIMENTAL
Intervention: MET
Number of subjects: 344
Study 20483060 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study 17855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncircumcised men
Number of subjects: 2771
Study 17855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 2771
Study 17855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married or having a live-in female partner
Number of subjects: 2771
Study 17855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferring 'dry' sex
Number of subjects: 2771
Study 17855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported penile cuts or abrasions during sex
Number of subjects: 2771
Study 17855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing lifetime sexual partners
Number of subjects: 2771
Study 17855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-student occupation
Number of subjects: 2771
Study 17855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported condom use at last sex
Number of subjects: 2771
Study 18675744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous)
Number of subjects: 71
Study 18675744 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic NaCl solution)
Number of subjects: 71
Study 15500496 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation with muscle relaxants and inhalation anesthesia
Number of subjects: 36
Study 15500496 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation with halothane in 100% oxygen
Number of subjects: 36
Study 11207493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical brush and Ayre's wooden spatula
Number of subjects: 1000
Study 11207493 — intervention group
Group type: COMPARATOR
Intervention: Acellon Combi
Number of subjects: 1000
Study 11207493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical brush
Number of subjects: 1000
Study 9006420 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized macular hole surgery
Number of subjects: 120
Study 8410120 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of tumor necrosis (TN)
Number of subjects: 728
Study 3317346 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived hepatitis B vaccine (10, 20, 40 micrograms)
Number of subjects: 0
Study 3317346 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (20 micrograms)
Number of subjects: 0
Study 3317346 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both yeast-derived and plasma-derived vaccines)
Number of subjects: 0
Study 3317346 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination of subjects with no detectable anti-HBs
Number of subjects: 0
Study 30786916 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction carbon ion radiotherapy (CIRT) boost followed by 60 GyE of proton irradiation with concurrent temozolomide (TMZ) at 75 mg/m2.
Number of subjects: 0
Study 30786916 — intervention group
Group type: EXPERIMENTAL
Intervention: CIRT boost (dose determined in Phase I of this trial) followed by 60 GyE of proton irradiation with concurrent TMZ.
Number of subjects: 0
Study 30786916 — intervention group
Group type: COMPARATOR
Intervention: 60 GyE (2 GyE per fraction) of proton irradiation with concurrent TMZ (control arm).
Number of subjects: 0
Study 29916264 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Dispersive X-ray Fluorescence (EDXRF) spectrometry
Number of subjects: 59
Study 29916264 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical calibration approach using EDXRF
Number of subjects: 59
Study 29916264 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical calibration approach using EDXRF
Number of subjects: 59
Study 29916264 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected EDXRF values using fixed bias subtraction and proportional bias correction
Number of subjects: 59
Study 27272673 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) solution at 24 ml·kg·h
Number of subjects: 36
Study 27272673 — intervention group
Group type: COMPARATOR
Intervention: Acetated Ringer's solution at 24 ml·kg·h
Number of subjects: 36
Study 27272673 — intervention group
Group type: COMPARATOR
Intervention: Acetated Ringer's solution at 2 ml·kg·h
Number of subjects: 36
Study 24565384 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.025 mg kg(‐1) intravenously
Number of subjects: 0
Study 24565384 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 0
Study 21558158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Self‐help (CBS)
Number of subjects: 45
Study 21558158 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 45
Study 21162928 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized vaginal surgery
Number of subjects: 150
Study 21162928 — intervention group
Group type: COMPARATOR
Intervention: Kelly-Kennedy operation
Number of subjects: 150
Study 17927499 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary beta carotene intake
Number of subjects: 540
Study 17927499 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma beta carotene levels
Number of subjects: 540
Study 17927499 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Number of subjects: 540
Study 15738352 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel with eptifibatide
Number of subjects: 120
Study 15738352 — intervention group
Group type: COMPARATOR
Intervention: 600 mg clopidogrel without eptifibatide
Number of subjects: 120
Study 15738352 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel without eptifibatide
Number of subjects: 120
Study 15738352 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 120
Study 11930332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (10,000 IU of retinyl palmitate)
Number of subjects: 400
Study 9452835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell anemia patients
Number of subjects: 25
Study 9452835 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls with sickle cell anemia
Number of subjects: 25
Study 9452835 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with sickle cell anemia
Number of subjects: 25
Study 7657850 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg oral controlled-release morphine sulfate tablet with naltrexone blockade
Number of subjects: 23
Study 7657850 — intervention group
Group type: COMPARATOR
Intervention: two 100-mg MSC tablets
Number of subjects: 23
Study 2675301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 210
Study 2675301 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 210
Study 2675301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 48053 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 76
Study 48053 — intervention group
Group type: COMPARATOR
Intervention: Control anaesthetic (fiben using halothane-free apparatus)
Number of subjects: 76
Study 31651289 — intervention group
Group type: EXPERIMENTAL
Intervention: Snacking before bed
Number of subjects: 1004
Study 31651289 — intervention group
Group type: COMPARATOR
Intervention: Watching TV
Number of subjects: 1004
Study 31651289 — intervention group
Group type: COMPARATOR
Intervention: Sleeping during leisure periods
Number of subjects: 1004
Study 31651289 — intervention group
Group type: COMPARATOR
Intervention: Bicycling as a means of transport to school
Number of subjects: 1004
Study 28703903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.1 to 3 mg/kg as a single dose once every 4 weeks or 2 mg/kg once every 8 weeks
Number of subjects: 299
Study 28703903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 25891232 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking in the past 30 days
Number of subjects: 278
Study 25891232 — intervention group
Group type: EXPERIMENTAL
Intervention: No alcohol use in the past 30 days
Number of subjects: 278
Study 25891232 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily or nearly daily drinking
Number of subjects: 278
Study 25891232 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with frequency of alcohol consumption
Number of subjects: 278
Study 25891232 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent heavy drinking, alcohol abuse/dependence, and unprotected sex under the influence of alcohol
Number of subjects: 278
Study 23899425 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of Organizational Attributes in Primary Care (SOAPC)
Number of subjects: 178
Study 21251985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 50μg/kg administered on Days 1 and 56 with subsequent doses at 8-week intervals (up to a total of eight infusions)
Number of subjects: 281
Study 19117313 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA Cream (EC)
Number of subjects: 30
Study 19117313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lubricant ointment)
Number of subjects: 30
Study 17762314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 64
Study 17762314 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 64
Study 15247553 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once daily
Number of subjects: 810
Study 15247553 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 810
Study 15247553 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 810
Study 15247553 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 810
Study 15011220 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard advanced cardiac life support (ACLS) intervention with early empiric administration of bicarbonate (1-mEq/kg dose)
Number of subjects: 874
Study 15011220 — intervention group
Group type: COMPARATOR
Intervention: Standard advanced cardiac life support (ACLS) intervention without early empiric administration of bicarbonate
Number of subjects: 874
Study 11426094 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg intravenously at the time of dural closure
Number of subjects: 170
Study 11426094 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 170
Study 9437202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapies
Number of subjects: 16
Study 8290902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 1 g bid
Number of subjects: 865
Study 8290902 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 1 g bid
Number of subjects: 865